Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocyto...

全面介绍

书目详细资料
Main Authors: Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T. Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N. Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa
格式: 文件
语言:English
出版: Wiley 2023-11-01
丛编:HemaSphere
在线阅读:http://journals.lww.com/10.1097/HS9.0000000000000963

因特网

http://journals.lww.com/10.1097/HS9.0000000000000963

相似书籍